Carol Budgin
Critical Care Medicine · Munster, INNPI 1912056482
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 176 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by Novartis at 25.1% of the total.
Across 176 payments — averaging $17.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$786
- Merck$432
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$345
- Johnson & Johnson$302
- Amgen$224
- AstraZeneca$174
- plus $865 from 16 others
What the payments were for
- Food & beverage$3,04897%
- Other$793%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 54 | $786 |
| Merck | 27 | $432 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 18 | $345 |
| Johnson & Johnson | 12 | $302 |
| Amgen | 12 | $224 |
| AstraZeneca | 11 | $174 |
| Scpharmaceuticals Inc. | 5 | $153 |
| E.r. Squibb & Sons, L.L.C. | 7 | $107 |
| Esperion Therapeutics, Inc. | 6 | $101 |
| Sanofi-aventis U.S. LLC | 4 | $83 |
| Baxter Healthcare | 2 | $79 |
| Boehringer Ingelheim | 3 | $67 |
| Abbott | 2 | $50 |
| Amarin Pharma, Inc. | 3 | $44 |
| Boston Scientific | 1 | $34 |
| Lexicon Pharmaceuticals, Inc. | 2 | $30 |
| Cook Medical LLC | 2 | $27 |
| Novo Nordisk | 1 | $26 |
| Vifor Pharma, Inc. | 1 | $19 |
| Pfizer | 1 | $19 |
| Atricure, Inc. | 1 | $15 |
| Medtronic | 1 | $12 |
How this compares
$3,128 in reported general payments places this provider in the 75th percentile of 158 critical care medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 33 | $48,927 |
| EliquisApixaban | 37 | $38,513 |
| Repatha SureclickEvolocumab | 36 | $29,859 |
| XareltoRivaroxaban | 25 | $28,695 |
| MultaqDronedarone Hcl | 13 | $15,381 |
| Repatha SyringeEvolocumab | 14 | $8,342 |
| Amiodarone Hcl | 29 | $2,201 |
| Ranolazine ErRanolazine | 12 | $1,532 |
| Metoprolol Succinate | 62 | $790 |
| Nebivolol Hcl | 21 | $568 |
| Hydralazine Hcl | 42 | $524 |
| Doxazosin Mesylate | 26 | $478 |
| Alprazolam | 57 | $447 |
| Atorvastatin Calcium | 66 | $439 |
| ClopidogrelClopidogrel Bisulfate | 36 | $409 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $786 | $48,92733 claims |
| PfizerEliquis | $19 | $38,51337 claims |
| Johnson & JohnsonXarelto | $302 | $28,69525 claims |
| Sanofi-aventis U.S. LLCMultaq | $83 | $15,38113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 158 critical care medicine providers in Indiana.
Other critical care medicine in Munster
- Ibraheem YousefMunster$3K
- Virginia HylandMunster$2K
- Bassel EricsoussiMunster$2K
- Vrushank PatelIndianapolis$142K
- Matthew KoscielskiSouth Bend$118K
- Christopher KnieseIndianapolis$44K
- Stanley NasrawayIndianapolis$34K
- Ismail Al-AniSouth Bend$25K
- Horia DraghiciuRichmond$21K
- Shashikumar GowdaTerre Haute$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.